WHIPPANY, N.J., Jan. 8, 2015 /PRNewswire/ -- Data from a recent patient satisfaction study conducted by J.D. Power has found that Bayer blood glucose meters ranked highest in overall satisfaction among patients with diabetes. In the study of 2,024 people with type 1 or type 2 diabetes who use blood glucose meters (BGMS), Bayer ranked highest in satisfaction among competitors meter manufacturers. Bayer was also the only manufacturer to receive 5 out of 5 on the JDPower.com Power Circle Ratings™ for consumers.
The J.D. Power 2014 U.S. Blood Glucose Meter Satisfaction Study is a patient satisfaction benchmarking study. It was fielded in September 2014 and reported overall satisfaction scores for 4 meter manufacturers, Abbott Laboratories, Bayer, LifeScan and Roche Diagnostics. The J.D. Power index methodology uses an online patient survey to gather data about six separate factors of patient experience: performance; ease of use; design; features; cost of test strips; and training. These responses are used to calculate an overall patient satisfaction score.
"Blood glucose meters are an important tool for people with diabetes to help better manage their condition and patient satisfaction is a key element in the effectiveness of the meters. J.D. Power is the gold standard of measuring consumer satisfaction and these results demonstrate that Bayer has outperformed competitors based on multiple measures of patient satisfaction," said Russell Newsome, Country Division Head of US and Canada, Bayer HealthCare Diabetes Care. "Bayer is thrilled by these results, as they show our longstanding commitment to providing people with diabetes with the highest quality products to help them manage their condition."
This commitment began when Bayer (trading as Ames in 1965) developed and brought to market the first blood glucose test strip, the Dextrostix®, a paper reagent strip for use by doctors1.The company then created the first blood glucose meter in 1970 to allow patients to read these strips and provide them with a number associated with the reading. Bayer's support for people with diabetes continues today through its currently available range of blood glucose monitors, including the CONTOUR® NEXT portfolio.
In addition to these results, Bayer recently presented data from two new analyses of previously published studies at the Diabetes Technology Society Annual Meeting 2014 that demonstrated the impressive accuracy of Bayer meters2,3.
"In addition to patient satisfaction, accurate blood glucose readings are critical to helping people with diabetes manage their condition effectively and could be clinically important for them," added Russell Newsome. "Bayer HealthCare believes that the combination of highly satisfied patients and highly accurate meters can aid in better patient care."
About CONTOUR® NEXT meter platforms
The newest portfolio of high-accuracy BGMS developed by Bayer contains the flavin adenine dinucleotide-glucose dehydrogenase (FAD-GDH) enzyme in combination with a proprietary electrochemical mediator. The proprietary electrochemical mediator and meter algorithm utilized in the CONTOUR NEXT portfolio of BGMS provide a stable, high signal-to-noise ratio that facilitates accurate determination of blood glucose readings, even at low blood glucose levels. Bayer's CONTOUR NEXT platform are the only products on the market that use this unique chemical technology. The new technology also ensures that the system remains accurate under a wide range of storage conditions, corrects for common errors such as hematocrit, and, with the exception of xylose, is not affected by many common interfering substances in the blood, (e.g., acetaminophen, vitamin C). For more information about Bayer's CONTOUR NEXT portfolio of products visit: www.BayerContour.com.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. For more information, please visit www.healthcare.bayer.com.
Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
1 Clarke S F and Foster J R. British Journal Of Biomedical Science (2012) 69 (2) 83-93
2 Pardo, S, Pflug, B, Dunne, N, Simmons, D. Presented at the 14th Annual Meeting of the Diabetes Technology Society, November 6-8, 2014, Bethesda, Maryland.
3 Pflug, B, Pardo, S, T, Simmons, D. Presented at the 14th Annual Meeting of the Diabetes Technology Society, November 6-8, 2014, Bethesda, Maryland.
SOURCE Bayer HealthCare